Novel method using rotational thromboelastography analysis for intraoperative management of device patient with heparin-induced thrombocytopenia

Jessika Iwanski, Toshinobu Kazui, Phat Le Tran, Robyn Basken, Raymond K Wong, Zain I Khalpey

Research output: Contribution to journalArticle

Abstract

Heparin-induced thrombocytopenia (HIT) is a prothrombotic disease in response to previous heparin exposure. Direct thrombin inhibitors are suitable candidates for the prophylaxis of thrombosis in patients with HIT. Currently activated clotting time and activated partial thromboplastin time are used to guide dosing and monitor anticoagulation. These assays provide a measure of clot initiation and only account for a small fraction of the coagulation pathway. In this case study we performed rotational thromboelastography (ROTEM) analysis on a patient with HIT implanted with a continuous-flow CentriMag device for left ventricular support. ROTEM evaluation confirmed a decline in activated clotting time values and provided information regarding intrinsic and extrinsic clotting times. Monitoring ROTEM parameters aided in the detection of coagulopathies and the decision to administer platelet or fresh frozen plasma products. Utilizing ROTEM can guide clinical decisions in transfusions, particularly in patients with HIT, where platelet and fibrinogen levels can be safely maintained to prevent thrombosis.

Original languageEnglish (US)
JournalBlood Coagulation and Fibrinolysis
DOIs
StateAccepted/In press - Jan 11 2016

Fingerprint

Thrombelastography
Thrombocytopenia
Heparin
Equipment and Supplies
Thrombosis
Blood Platelets
Antithrombins
Partial Thromboplastin Time
Fibrinogen

ASJC Scopus subject areas

  • Hematology

Cite this

@article{5b594d39ba644402a5f825ff93f7fae7,
title = "Novel method using rotational thromboelastography analysis for intraoperative management of device patient with heparin-induced thrombocytopenia",
abstract = "Heparin-induced thrombocytopenia (HIT) is a prothrombotic disease in response to previous heparin exposure. Direct thrombin inhibitors are suitable candidates for the prophylaxis of thrombosis in patients with HIT. Currently activated clotting time and activated partial thromboplastin time are used to guide dosing and monitor anticoagulation. These assays provide a measure of clot initiation and only account for a small fraction of the coagulation pathway. In this case study we performed rotational thromboelastography (ROTEM) analysis on a patient with HIT implanted with a continuous-flow CentriMag device for left ventricular support. ROTEM evaluation confirmed a decline in activated clotting time values and provided information regarding intrinsic and extrinsic clotting times. Monitoring ROTEM parameters aided in the detection of coagulopathies and the decision to administer platelet or fresh frozen plasma products. Utilizing ROTEM can guide clinical decisions in transfusions, particularly in patients with HIT, where platelet and fibrinogen levels can be safely maintained to prevent thrombosis.",
author = "Jessika Iwanski and Toshinobu Kazui and {Le Tran}, Phat and Robyn Basken and Wong, {Raymond K} and Khalpey, {Zain I}",
year = "2016",
month = "1",
day = "11",
doi = "10.1097/MBC.0000000000000516",
language = "English (US)",
journal = "Blood Coagulation and Fibrinolysis",
issn = "0957-5235",
publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - Novel method using rotational thromboelastography analysis for intraoperative management of device patient with heparin-induced thrombocytopenia

AU - Iwanski, Jessika

AU - Kazui, Toshinobu

AU - Le Tran, Phat

AU - Basken, Robyn

AU - Wong, Raymond K

AU - Khalpey, Zain I

PY - 2016/1/11

Y1 - 2016/1/11

N2 - Heparin-induced thrombocytopenia (HIT) is a prothrombotic disease in response to previous heparin exposure. Direct thrombin inhibitors are suitable candidates for the prophylaxis of thrombosis in patients with HIT. Currently activated clotting time and activated partial thromboplastin time are used to guide dosing and monitor anticoagulation. These assays provide a measure of clot initiation and only account for a small fraction of the coagulation pathway. In this case study we performed rotational thromboelastography (ROTEM) analysis on a patient with HIT implanted with a continuous-flow CentriMag device for left ventricular support. ROTEM evaluation confirmed a decline in activated clotting time values and provided information regarding intrinsic and extrinsic clotting times. Monitoring ROTEM parameters aided in the detection of coagulopathies and the decision to administer platelet or fresh frozen plasma products. Utilizing ROTEM can guide clinical decisions in transfusions, particularly in patients with HIT, where platelet and fibrinogen levels can be safely maintained to prevent thrombosis.

AB - Heparin-induced thrombocytopenia (HIT) is a prothrombotic disease in response to previous heparin exposure. Direct thrombin inhibitors are suitable candidates for the prophylaxis of thrombosis in patients with HIT. Currently activated clotting time and activated partial thromboplastin time are used to guide dosing and monitor anticoagulation. These assays provide a measure of clot initiation and only account for a small fraction of the coagulation pathway. In this case study we performed rotational thromboelastography (ROTEM) analysis on a patient with HIT implanted with a continuous-flow CentriMag device for left ventricular support. ROTEM evaluation confirmed a decline in activated clotting time values and provided information regarding intrinsic and extrinsic clotting times. Monitoring ROTEM parameters aided in the detection of coagulopathies and the decision to administer platelet or fresh frozen plasma products. Utilizing ROTEM can guide clinical decisions in transfusions, particularly in patients with HIT, where platelet and fibrinogen levels can be safely maintained to prevent thrombosis.

UR - http://www.scopus.com/inward/record.url?scp=84954357618&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84954357618&partnerID=8YFLogxK

U2 - 10.1097/MBC.0000000000000516

DO - 10.1097/MBC.0000000000000516

M3 - Article

C2 - 26757013

AN - SCOPUS:84954357618

JO - Blood Coagulation and Fibrinolysis

JF - Blood Coagulation and Fibrinolysis

SN - 0957-5235

ER -